Patents by Inventor Kiyohiro Samizu
Kiyohiro Samizu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9242973Abstract: The present invention provides a hydrate of N-[(4S)-2-amino-2?,2?-dimethyldispiro[1,3-oxazole-4,4?-chromene-3?,3?-oxetan]-6?-yl]-5-chloropyridine-2-carboxamide which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by ?-secretase activity, hydrolysis of a ?-secretase site of a ?-amyloid precursor protein, and/or ?-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.Type: GrantFiled: January 22, 2015Date of Patent: January 26, 2016Assignee: COMENTIS, INC.Inventors: Ryosuke Munakata, Makoto Inoue, Hiroaki Tominaga, Shingo Yamasaki, Yasuhiro Shiina, Kiyohiro Samizu, Hisao Hamaguchi, Lin Hong
-
Publication number: 20150225386Abstract: The present invention provides a hydrate of N-[(4S)-2-amino-2?,2?-dimethyldispiro[1,3-oxazole-4,4?-chromene-3?,3?-oxetan]-6?-yl]-5-chloropyridine-2-carboxamide which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by ?-secretase activity, hydrolysis of a ?-secretase site of a ?-amyloid precursor protein, and/or ?-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.Type: ApplicationFiled: January 22, 2015Publication date: August 13, 2015Inventors: Ryosuke MUNAKATA, Makoto INOUE, Hiroaki TOMINAGA, Shingo YAMASAKI, Yasuhiro SHIINA, Kiyohiro SAMIZU, Hisao HAMAGUCHI, Lin HONG
-
Patent number: 8975415Abstract: The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by ?-secretase activity, hydrolysis of a ?-secretase site of a ?-amyloid precursor protein, and/or ?-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.Type: GrantFiled: February 27, 2014Date of Patent: March 10, 2015Assignee: CoMentis, Inc.Inventors: Ryosuke Munakata, Makoto Inoue, Hiroaki Tominaga, Shingo Yamasaki, Yasuhiro Shina, Kiyohiro Samizu, Hisao Hamaguchi, Lin Hong
-
Patent number: 8822688Abstract: [Problem] To provide a compound useful as medicine having PDE4B inhibitory activity, in particular, as an active ingredient of a composition for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like. [Measures for Solution] The present inventors examined compounds having PDE4B inhibitory activity and found that a tricyclic or tetracyclic imidazo[1,2-a]pyridine derivative or salts thereof had a superior PDE4B inhibitory activity, thereby completing the present invention. The imidazo[1,2-a]pyridine derivative can be used as an agent for treating or preventing schizophrenia, Alzheimer's disease, dementia, depression and the like.Type: GrantFiled: October 26, 2012Date of Patent: September 2, 2014Assignee: Astellas Pharma Inc.Inventors: Kiyohiro Samizu, Naoyuki Masuda, Kazuhiko Iikubo, Yohei Koganemaru, Noriyuki Kawano, Junya Ohmori, Yasuyuki Mitani, Keni Ni
-
Publication number: 20140179695Abstract: The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by ?-secretase activity, hydrolysis of a ?-secretase site of a ?-amyloid precursor protein, and/or ?-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.Type: ApplicationFiled: February 27, 2014Publication date: June 26, 2014Applicants: CoMentis, Inc., ASTELLAS PHARMA INC.Inventors: Ryosuke MUNAKATA, Makoto INOUE, Hiroaki TOMINAGA, Shingo YAMASAKI, Yasuhiro SHIINA, Kiyohiro SAMIZU, Hisao HAMAGUCHI, Lin HONG
-
Patent number: 8207199Abstract: A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent FAAH inhibitory activity, thereby completing the present invention. The compound of the present invention is confirmed to have an excellent FAAH inhibitory activity and an antiallodynic effect in rat models with neuropathic pain, and thus is useful as an agent for preventing and/or an agent for treating neuropathic pain.Type: GrantFiled: July 13, 2009Date of Patent: June 26, 2012Assignee: Astellas Pharma Inc.Inventors: Satoshi Aoki, Ryosuke Munakata, Noriyuki Kawano, Kiyohiro Samizu, Hiromasa Oka, Takahiro Ishii, Takashi Sugane
-
Publication number: 20110118311Abstract: A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent FAAH inhibitory activity, thereby completing the present invention. The compound of the present invention is confirmed to have an excellent FAAH inhibitory activity and an antiallodynic effect in rat models with neuropathic pain, and thus is useful as an agent for preventing and/or an agent for treating neuropathic pain.Type: ApplicationFiled: July 13, 2009Publication date: May 19, 2011Inventors: Satoshi Aoki, Ryosuke Munakata, Noriyuki Kawano, Kiyohiro Samizu, Hiromasa Oka, Takahiro Ishii, Takashi Sugane
-
Patent number: 7176219Abstract: There is provided an acid addition salt of (?)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (?)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (?)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.Type: GrantFiled: May 13, 2005Date of Patent: February 13, 2007Assignee: Astellas Pharma Inc.Inventors: Masahiko Hayakawa, Kiyohiro Samizu, Hiroshi Uebayashi, Ken Ikeda, Makoto Takeuchi
-
Publication number: 20060205770Abstract: There is provided an acid addition salt of (?)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (?)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (?)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.Type: ApplicationFiled: May 13, 2005Publication date: September 14, 2006Inventors: Masahiko Hayakawa, Kiyohiro Samizu, Hiroshi Uebayashi, Ken Ikeda, Makoto Takeuchi
-
Publication number: 20050090498Abstract: There is provided medicaments, particularly a vascular endothelial growth factor (VEGF) inhibitor which is useful as a therapeutic drug for solid tumors, diabetic retinopathy and the like diseases in which angiogenesis is taking a role. That is, since a novel 3-quinolin-2(1H)-ylideneindolin-2-one derivative or a salt thereof has good VEGF inhibitory action, angiogenesis inhibitory action and anti-tumor action, it is useful as ideal VEGF inhibitor, angiogenesis inhibitor and anti-tumor agent.Type: ApplicationFiled: May 23, 2002Publication date: April 28, 2005Inventors: Kiyohiro Samizu, Hiroyuki Hisamichi, Akira Matsuhisa, Isao Kinoyama, Masahiko Hayakawa, Nobuaki Taniguchi, Yukitaka Ideyama, Sadao Kuromitsu, Kiyoshi Yahiro, Minoru Okada
-
Publication number: 20040010037Abstract: This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.Type: ApplicationFiled: June 30, 2003Publication date: January 15, 2004Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.Inventors: Nobuaki Taniguchi, Isao Kinoyama, Takashi Kamikubo, Akira Toyoshima, Kiyohiro Samizu, Eiji Kawaminami, Masakazu Imamura, Hiroyuki Moritomo, Akira Matsuhisa, Masaaki Hirano, Yoji Miyazaki, Eisuke Nozawa, Minoru Okada, Hiroshi Koutoku, Mitsuaki Ohta
-
Patent number: 6673799Abstract: This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.Type: GrantFiled: March 21, 2001Date of Patent: January 6, 2004Assignee: Yamanouchi Pharmaceutical Co. Ltd.Inventors: Nobuaki Taniguchi, Isao Kinoyama, Takashi Kamikubo, Akira Toyoshima, Kiyohiro Samizu, Eiji Kawaminami, Masakazu Imamura, Hiroyuki Moritomo, Akira Matsuhisa, Masaaki Hirano, Yoji Miyazaki, Eisuke Nozawa, Minoru Okada, Hiroshi Koutoku, Mitsuaki Ohta
-
Patent number: 5769393Abstract: A display element for use in computer terminals, television displays and other information display devices capable of large capacity, full color display employing active elements, wherein an optical layer comprises liquid crystal and polymer dispersed in one another. The polymer comprises polymer grains directionally aligned in the optical layer by directional alignment of the liquid crystal, which is aligned by treatment provided relative to at least one of the substrates forming the display element. The polymer grains are developed from the polymerization of at least one polymer precursor containing at least one polymerizable portion and at least two aromatic rings with a coupling group provided between the aromatic rings. The polymer precursor contains, as at least one component, a polymer compound without an alkyl group spacer between the polymerizable portion and the aromatic rings.Type: GrantFiled: August 16, 1993Date of Patent: June 23, 1998Assignee: Seiko Epson CorporationInventors: Hidekazu Kobayashi, Kiyohiro Samizu
-
Patent number: 5680185Abstract: A polymer dispersed liquid crystal display apparatus has a liquid crystal/polymer medium formed between spatially disposed electrodes formed spatially disposed substrates. The medium includes a polymer phase and a liquid crystal phase having optical axes alignable together in a predetermined direction. A light absorption additive is included in the liquid crystal phase to provide light absorption when said optical axes are aligned in said predetermined direction so that in the presence or absence of an electric field applied between said electrodes, two different conditions are achieved comprising alignment and misalignment of the optical axes of the liquid crystal phase relative to the polymer phase so that in one condition, a light absorption state is created in the medium and in the other condition, a light scattering state is created in the medium.Type: GrantFiled: April 15, 1994Date of Patent: October 21, 1997Assignee: Seiko Epson CorporationInventors: Hidekazu Kobayashi, Kiyohiro Samizu, Eiji Chino, Jin Jei Wu
-
Patent number: 5305126Abstract: A polymer dispersed liquid crystal material (PDLC) device is fabricated by sealing a composite layer mixture of components comprising a polymer and liquid crystal material while both are in their liquid phase in a gap portion formed between two substrates of the device. A predetermined directional alignment is transmitted to the polymer via the liquid crystal material by means, for example, of formed directional alignment on surfaces in contact with the composite layer, such as, by deposited alignment films on a surface of at least one of the substrates. The predetermined directional alignment of the polymer is thereafter fixed by means of a polymer hardening method, such as, for example, by polymerization of a polymer precursor, so that the predetermined directional alignment of the polymer is permanently retain within the liquid crystal material, i.e., the polymer is in a solid phase and the liquid crystal material remains in its liquid phase.Type: GrantFiled: November 26, 1991Date of Patent: April 19, 1994Assignee: Seiko Epson CorporationInventors: Hidekazu Kobayashi, Kiyohiro Samizu, Jin-Jei Wu